Core Viewpoint - The transaction between the listed company and the target company aims to enhance business synergy and improve asset quality by integrating their operations in the biopharmaceutical sector, particularly focusing on cell culture products and CDMO services [1][2][3]. Group 1: Transaction Necessity and Business Integration - The listed company and the target company both operate in the biopharmaceutical sector, with the listed company focusing on cell culture products and CDMO services, while the target company specializes in CRO services for early-stage drug development [1][3]. - The transaction is seen as a strategic move to create synergies in business operations, customer bases, and international market strategies, enhancing the overall service offerings [2][4]. - The integration will allow the listed company to provide a comprehensive service chain from early drug development to commercial production, thereby improving customer retention and satisfaction [5][6]. Group 2: Financial Impact and Asset Quality Improvement - The transaction is expected to significantly improve the financial metrics of the listed company, with projected increases in total assets by 76.07% and net profit by 222.72% post-transaction [14][16]. - The integration will enhance the company's ability to withstand market fluctuations by diversifying its revenue streams, as CRO services are less correlated with the commercial production cycles of biopharmaceuticals [17][18]. - The merger will also reduce reliance on single product lines, allowing the company to offer a full range of services from early research to commercial production, thus strengthening its competitive position [17][19]. Group 3: Industry Trends and Strategic Alignment - The transaction aligns with industry trends where biopharmaceutical companies are increasingly seeking comprehensive service providers to streamline their drug development processes [19][20]. - The merger is consistent with industry practices where companies expand their capabilities through acquisitions to enhance service offerings and market competitiveness [19][20]. - The combined entity will be better positioned to compete with leading firms in the sector by offering integrated solutions that cover the entire drug development lifecycle [19][20]. Group 4: Integration Plans and Management Control - Post-transaction, the listed company plans to implement a comprehensive integration strategy that includes shared customer resources, joint marketing efforts, and unified management structures to enhance operational efficiency [22][23]. - The management team from the target company will remain in place, ensuring continuity while also integrating into the listed company's governance structure to facilitate effective oversight and control [26][30]. - The integration will focus on leveraging the strengths of both companies to create a robust platform for biopharmaceutical services, enhancing overall market presence and operational capabilities [22][23].

国泰海通证券股份有限公司 关于思瑞浦微电子科技（苏州）股份有限公司 开展外汇套期保值业务的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为思 瑞浦微电子科技（苏州）股份有限公司（以下简称"思瑞浦"、"公司"或"发 行人"）的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等有关规定，对思瑞浦开展外汇套期保值业务事项进行了审慎核查， 具体核查情况如下： 一、交易情况概述 （一）交易目的 （二）交易金额 结合 2025 年度生产经营计划和预期收付汇情况，公司对外汇风险敞口进行 了测算。2025 年度公司及控股子公司拟开展外汇套期保值业务交易金额累计不 超过 3,600 万美元（或其他等值外币）。 在上述额度和期限内，资金可循环使用，但开展期限内任一时点的交易金额 （含前述外汇套期保值业务的收益进行再交易的相关金额）不超过上述已审议额 度。预计动用的交易保证金和权利金上限（包括为交易而提供的担保物价值、预 计占用的金融机构授信额度、为应急措施所预留的保证金等）则不超过已审议额 度的 10% ...

相关资格的核查意见 中国（上海）自由贸易试验区商城路 618 号 国泰海通证券股份有限公司（以下简称"国泰海通"）受广东利扬芯片测试股 份有限公司（以下简称"利扬芯片"或"公司"）股东黄兴、海南扬致企业管理合伙 企业（有限合伙）、海南扬宏企业管理合伙企业（有限合伙）、黄主、谢春兰（以 下合称"出让方"）委托，组织实施本次利扬芯片首发前股东向特定机构投资者询 价转让（以下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 4 号——询价转让和配售（2025 年 3 月修订）》（以下简称"《询价转让和配售指引》"）等相关规定，国泰海通 对参与本次询价转让股东的相关资格进行核查，并出具本核查意见。 国泰海通证券股份有限公司 关于广东利扬芯片测试股份有限公司 一、本次询价转让的委托 股东向特定机构投资者询价转让股份 国泰海通收到出让方关于本次询价转让的委托，委托国泰海通组织实施本次 询价转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 根据 ...

国泰海通证券股份有限公司 关于浙江中力机械股份有限公司 首次公开发行网下配售限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 浙江中力机械股份有限公司（以下简称"中力股份"、"公司"）首次公开发行 股票并在主板上市的保荐机构，负责对中力股份的持续督导工作。根据《证券发 行上市保荐业务管理办法》《上海证券交易所股票上市规则》《上海证券交易所 上市公司自律监管指引第11号——持续督导》 《上海证券交易所上市公司自律监 管指引第1号——规范运作》等有关法律、法规和规范性文件的要求，对中力股 份首次公开发行网下配售限售股上市流通事项进行了审慎核查，具体核查情况 及核查意见如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意浙江中力机械股份有限公司首次 公开发行股票注册的批复》（证监许可2024230号），并经上海证券交易所同意 ，浙江中力机械股份有限公司首次公开发行人民币普通股（A股）6,100万股，并 于2024年12月24日在上海证券交易所主板上市交易。公司首次公开发行股票完 成后，总股本为401,000,000股，其中有限售条件流通股351,17 ...

国泰海通证券股份有限公司 关于上海骄成超声波技术股份有限公司 差异化分红事项的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海骄成超声波技术股份有限公司（以下简称"骄成超声"或"公司"）首次公 开发行股票并上市持续督导保荐机构，根据《中华人民共和国公司法》《中华人 《上海证券交易所上市公司自律监管指引第 7 号——回购股份》 民共和国证券法》 等相关法律、行政法规、部门规章及其他规范性文件的相关规定，对公司 2024 年度利润分配所涉及的差异化分红（以下简称"本次差异化分红"）相关事项进 行了审慎核查，并出具核查意见如下： 一、本次差异化分红的原因 公司于 2024 年 2 月 4 日召开第一届董事会第二十次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用不低于人民币 股份，回购价格不超过 102.56 元/股，主要用于维护公司价值和股东权益，回购 期限为自公司董事会审议通过本次回购股份方案之日起 3 个月。 公司于 2024 年 7 月 18 日召开第二届董事会第三次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司 ...

国泰海通证券股份有限公司 关于吉林省中研高分子材料股份有限公司 部分募投项目调整内部投资结构及使用自有资金支付研发 人员费用并以募集资金等额置换的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为吉 林省中研高分子材料股份有限公司（以下简称"中研股份"、"公司"或"发行 人"）首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业 务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》等有关 法律法规和规范性文件的要求，公司对部分募投项目调整内部投资结构及使用自 有资金支付研发人员费用并以募集资金等额置换的事项进行了核查，核查情况如 下： 一、变更募集资金投资项目的概述 （一）募集资金基本情况 经中国证券监督管理委员会《关于同意吉林省中研高分子材料股份有限公司 首次公开发行股票注册的批复》（证监许可﹝2023﹞1531 号）（注册生效日为 民币普通股（A 股）股票发行 30,420,000 股，发行价格为 29.66 ...

Core Viewpoint - The company is utilizing its own funds to pay for investment projects and will replace these with raised funds in a timely manner, ensuring compliance with regulatory requirements and maintaining operational efficiency [1][6]. Summary by Sections 1. Basic Information on Raised Funds - The company issued 9,874,453 shares at a price of 70.89 RMB per share, raising a total of approximately 700 million RMB, with a net amount of about 689.52 million RMB after deducting issuance costs [1][2]. 2. Investment Project Details - The raised funds will primarily be allocated to the MEMS process wafer testing probe R&D project, with a total investment of 767.8 million RMB, of which 700 million RMB is planned to be funded by the raised capital [2]. 3. Reasons and Procedures for Using Own Funds - The company opted to use its own funds for project expenses due to operational challenges in using raised funds directly for certain payments, such as employee salaries and foreign supplier payments [4][5]. The process involves internal approval and regular reporting to ensure transparency [4]. 4. Impact on Daily Operations - The decision to use own funds is expected to enhance operational management efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of these projects [5][6]. 5. Review Procedures and Opinions - Both the board of directors and the supervisory board have approved the use of own funds for project expenses, confirming that the necessary approval processes were followed and that there is no impact on the intended use of raised funds [5][6].

报告导读： 风险提示：行业竞争加剧，宏观环境疲软，海外市场开拓受阻等 公司概要：伟仕佳杰是亚太地区重要的科技产品渠道开发与技术方案集成服务商。服务网络高度覆盖一 带一路区域，透过 50000 家渠道伙伴，服务 19 亿人群。公司是华为、新华三、阿里、腾讯、曙光、联 想、惠普、戴尔、微软、苹果等 300 多家世界 500 强科技企业，在亚太地区最重要的合作伙伴。业务覆 盖云计算/大数据、人工智能、数据存储、数据分析、基础建设、网络安全、方案交付、移动互联、游 戏娱乐、物联应用、可穿戴设备及虚拟现实产品等十二大领域，在云生态建设、IT 运维服务、供应链 金融、信创产业等拓展出全新版图，为全链路伙伴提供高效、持续、多元的商业生态闭环。财务数据： 2015 年 -2024 年收入 /扣 非 归 母 净 利 CAGR 分 别 为7.7%/9.9%。1Q25 年公司营业收入同比增长 16- 17%，毛利同比增长 20-21%，1Q25 年公司归属于股东净利同比增长 28-29%，我们预计或受益于海外 分销业务结构优化及国产品牌市占率持续提升。 逻辑 1：传统主业收益 AI 浪潮。佳杰云星 AI 算力管理与调度平台、AI ...

Core Insights - The 2025 Lujiazui Forum focused on the integration of technology and finance, emphasizing the development of a comprehensive financial service system for innovative enterprises in Shanghai [2][5] - Shanghai aims to enhance its role as a global financial center by fostering a supportive ecosystem for technology-driven industries and improving financial products tailored to various stages of enterprise development [3][4] Group 1: Event Overview - The event included a concentrated release of financial services for the entire lifecycle of technology innovation, a signing ceremony with the Greek Shipping Finance Management Association, and roundtable discussions [2][5] - Key officials from Shanghai's financial sector and representatives from various financial institutions and technology companies participated, highlighting the collaborative effort to support strategic emerging industries [2][3] Group 2: Financial Products Released - A range of financial products was launched to support small and medium-sized technology enterprises, focusing on digital credit, capital market linkage, and cross-institution collaboration [3][4] - Initial stage products include "Innovation Drug Loan" from Agricultural Bank of China and "Smart Intellectual Property Loan" from Bank of Communications, among others [3] - Growth stage products include "Puxin Loan" from Shanghai Pudong Development Bank and "Investment-Loan Linked Loan" from Industrial Bank, while mature stage products include "ICBC Treasury" and "Index Investment Series Products" [4] Group 3: Collaborative Efforts - A memorandum of cooperation was signed between Shanghai Financial Association and the Greek Shipping Finance Management Association, indicating a commitment to enhance collaboration in shipping finance and green finance [4] - The event featured two roundtable discussions addressing capital flow support for hard technology enterprises and financial collaboration to build future industry hubs [5]

Core Viewpoint - The company is actively advancing its fundraising projects and production capacity, aiming for high-quality output and market expansion, with significant growth in revenue and net profit reported for Q1 2025. Group 1: Fundraising Projects and Production Capacity - The company adheres to a principle of "overall planning and phased implementation" to ensure timely and high-quality production of its fundraising projects [2] - The "annual production of 2,000 sets of industrial digital printing equipment and consumables intelligent factory" project has nearly reached full production capacity in 2024 [2] - The construction of the "integrated printing industry base project" with an annual output of 47,000 tons of digital printing ink is expected to be completed in 2025, enhancing the company's competitiveness in key consumables [2] Group 2: Business Development and Future Plans - In 2024, the company achieved significant revenue growth in digital printing and automated sewing equipment, with total revenue exceeding 280 million yuan, representing a year-on-year increase of 37.67% and 114.66% respectively [3] - The company plans to expand its product offerings in digital printing equipment and automated sewing machines, focusing on both product and market development [4] - The company aims to enhance its product matrix to meet diverse customer needs and improve sales channels, including the development of domestic and international sales agencies [4] Group 3: Financial Performance - In Q1 2025, the company reported a main revenue of 478 million yuan, a year-on-year increase of 29.79%, and a net profit attributable to shareholders of 108 million yuan, up 25.2% [12] - The company's gross profit margin stands at 42.84%, with a debt ratio of 19.66% [12] Group 4: Market Strategy and Risk Management - The company maintains a "risk controllable" principle in managing accounts receivable, ensuring low bad debt rates and optimizing overall process control [6] - The impact of US-China tariffs on the company's business is minimal, as most exports are directed towards South Asian and European markets, with a low proportion of products exported to the US [10] - The company plans to strengthen its overseas market presence by enhancing service capabilities and optimizing supply chain management [11]